Dublin, Dec. 13, 2021 (GLOBE NEWSWIRE) -- The "Cell Based Assays Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
The global cell based assays market is expected to grow from $17.49 billion in 2020 to $19.29 billion in 2021 at a compound annual growth rate (CAGR) of 10.3%. The market is expected to reach $26.69 billion in 2025 at a CAGR of 8.5%.
Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, and Merck.
The cell based assays market consists of sales of cell based assays. Cell-based assays are analytical tools that are designed to study a mechanism or process of cellular function. Companies developing cell based assays provide consumables such as reagents, assays kits and microplates as well as instruments, services and software. This report includes sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels, and others.
High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (high content analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market.
Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries' need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation.
Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies.
Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the market for cell based arrays.
Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure.
For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation.
Key Topics Covered:
1. Executive Summary
2. Cell Based Assays Market Characteristics
3. Cell Based Assays Market Trends and Strategies
4. Impact Of COVID-19 On Cell Based Assays
5. Cell Based Assays Market Size and Growth
5.1. Global Cell Based Assays Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Cell Based Assays Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Cell Based Assays Market Segmentation
6.1. Global Cell Based Assays Market, Segmentation by Product & Service, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Consumables
- Instruments
- Services
- Software
6.2. Global Cell Based Assays Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Drug Discovery
- Basic Research
- ADME Studies
- Predictive Toxicology
- Others
6.3. Global Cell Based Assays Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Contract research organizations (CRO)
- Other end users
6.4. Global Cell Based Assays Market, Segmentation by Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Automated Handling
- Flow Cytometry
- Label-Free Detection
- High-Throughput Screening
- Others
6.5. Global Cell Based Assays Market, Segmentation by Consumables, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Reagents and Media
- Cells and Cell Lines
- Probes and Labels
6.6. Global Cell Based Assays Market, Segmentation by Instruments, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Microplates
- Microplate Readers
- High Throughput Screening
- Liquid Handling Systems
7. Cell Based Assays Market Regional and Country Analysis
7.1. Global Cell Based Assays Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Cell Based Assays Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Companies Mentioned
- Thermo Fisher
- Danaher
- Becton, Dickinson and Company
- GE Healthcare
- Merck
- Perkinelmer
- Promega
- Lonza
- Charles River Laboratories
- Cell Signaling Technology
- Cisbio
- Cell Biolabs
- Bio-Rad Laboratories
- DiscoveRx
- BioTek Instruments
- Biotium
- Abcam
- Creative Bioarray
- Corning
- Roche
- ProQinase
- Miltenyi Biotec
- BioAgilytix
- Enzo Life Sciences
- Aurelia Bioscience
- Selexis
- QGel
- BioVision
- Caliper Life Sciences
- Sigma-Aldrich
For more information about this report visit https://www.researchandmarkets.com/r/fqcy3r
